Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trius Therapeutics Inc.

Division of Merck & Co. Inc.
www.triusrx.com

Latest From Trius Therapeutics Inc.

Merck And The 'Strange Business' Of Antibiotics

Antibacterials have been part of Merck's mission for decades, despite the market challenges, and it's expecting two new approvals this year. Infectious disease VP Joan Butterton talks about tackling those challenges and incentives that may help the industry address antimicrobial resistance.

Infectious Diseases Research and Development Strategies

Cidara To Take Rezafungin Into Phase III In Two Severe Infection Indications

Two-week treatment data comparing the investigational echinocandin antifungal with caspofungin shows trend toward better cure rate with similar efficacy. Cidara plans Phase III trials for treatment and prevention of difficult-to-treat infections.
Research & Development Infectious Diseases

Finance Watch: NDA-Ready Impact Gets Commitment For Another $90m

Start-up Impact's new structured financing – its second fundraising event this month – will pay out in increments as fedratinib nears the market. Also, Ablynx closed its $200m US IPO; Chi-Med follow-on brings in $262m; and VCs gives Cydan $34m to launch new companies.

Financing Business Strategies

ICAAC 2015: Scrip Connects With Cidara, MerLion And Paratek

Scrip caught up with several biopharma executives on Sept. 18 during the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infection (ICC) in San Diego to discuss the status of their anti-infective drug development programs.

Dermatology Infectious Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Rx3 Pharmaceuticals Inc.
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Merck & Co. Inc.
  • Senior Management
  • Jeffrey Stein, PhD, Pres. & CEO
    Kenneth F Bartizal, PhD, Chief Dev. Officer
    Neil Abdollahian, VP, Corp. Dev.
    John Finn, PhD, CSO
    Craig Thompson, Chief Commerical Officer
  • Contact Info
  • Trius Therapeutics Inc.
    Phone: (858) 452-0370
    6310 Nancy Ridge Dr., Ste. 105
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register